# Miles Parkes

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/miles-parkes/

## Facts

| Field | Value |
| --- | --- |
| Citations | 64,128 |
| Field | Inflammatory Bowel Disease |
| h-index | 75 |
| i10-index | 164 |
| Last Known Institution | University of Cambridge |
| OpenAlex ID | https://openalex.org/A5066218040 |
| ORCID iD | https://orcid.org/0000-0002-6467-0631 |
| Works | 381 |

## Researcher papers

- [Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls](https://scholariq.org/papers/genome-wide-association-study-of-14-000-cases-of-seven-common-diseases-and-3-000/)
- [Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations](https://scholariq.org/papers/association-analyses-identify-38-susceptibility-loci-for-inflammatory-bowel/)
- [Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease](https://scholariq.org/papers/genome-wide-association-defines-more-than-30-distinct-susceptibility-loci-for/)
- [Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility](https://scholariq.org/papers/sequence-variants-in-the-autophagy-gene-irgm-and-multiple-other-replicating-loci/)
- [Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci](https://scholariq.org/papers/analysis-of-five-chronic-inflammatory-diseases-identifies-27-new-associations/)
- [Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study](https://scholariq.org/papers/predictors-of-anti-tnf-treatment-failure-in-anti-tnf-naive-patients-with-active/)
- [HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn’s Disease](https://scholariq.org/papers/hla-dqa1-05-carriage-associated-with-development-of-anti-drug-antibodies-to/)
- [A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial](https://scholariq.org/papers/a-biomarker-stratified-comparison-of-top-down-versus-accelerated-step-up/)
- [COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study](https://scholariq.org/papers/covid-19-vaccine-induced-antibody-responses-in-immunosuppressed-patients-with/)
- [Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study](https://scholariq.org/papers/mechanisms-and-management-of-loss-of-response-to-anti-tnf-therapy-for-patients/)

## Researcher topics

- [Inflammatory Bowel Disease](https://scholariq.org/topics/inflammatory-bowel-disease/)
- [Microscopic Colitis](https://scholariq.org/topics/microscopic-colitis/)
- [Helicobacter pylori-related gastroenterology studies](https://scholariq.org/topics/helicobacter-pylori-related-gastroenterology-studies/)
- [Immunodeficiency and Autoimmune Disorders](https://scholariq.org/topics/immunodeficiency-and-autoimmune-disorders/)
- [Celiac Disease Research and Management](https://scholariq.org/topics/celiac-disease-research-and-management/)

## Researcher university

- [University of Cambridge](https://scholariq.org/institutions/university-of-cambridge/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.